I3MT-3 (HMPSNE) is a potent, selective, and cell-membrane permeable inhibitor of3-Mercaptopyruvate sulfurtransferase (3MST)(IC₅₀=2.7 μM). I3MT-3 is inactive for other H2S/sulfane sulfur-producing enzymes. I3MT-3 targets a persulfurated cysteine residue located in the active site of 3MST^[1].

IC50: 2.7 μM (3-Mercaptopyruvate sulfurtransferase (3MST))^[1]

I3MT-3 (1 μM) is selective for 3MST and shows a high inhibitory activity (80–90%) even at 10 μM in cell lysate of 3MST-overexpressing HEK293 cells. Besides, it is almost inactive towards the other two H2S-producing enzymes even at 100 μM^[1].
I3MT-3 (1 μM) shows a high selectivity for 3MST, it completely suppresses the 3MST activity in COS7 cells living cells^[1].
I3MT-3 produces a concentration-dependent inhibition of the AzMC (the fluorescent H2S probe) signal when incubated with purified human recombinant enzyme, the inhibition of the catalytic activity of 3-MST produces a concentration-dependent inhibition of H2S production with an IC₅₀of 13.6 μM^[1].
I3MT-3 shows a dose-dependent inhibition of 3-MST activity from CT26 homogenates, which contain the murine form of the enzyme. The IC₅₀ of HMPSNE for murine 3-MST is calculated as 2.3 μM with a cozncentration-dependent decrease of AzMC fluorescence^[1].
I3MT-3 (10 μM-100 μM; after 3 h probe AzMC) causes a partial inhibition of the signal, while at 100 μM, HMPSNE causes a complete inhibition of the AzMC-guided H2S fluorescence at 100 μM, Additionally, HMPSNE is capable of inhibiting its target in situ in CT26 cells (with an IC₅₀ of approximately 30 μM)^[2].
I3MT-3 (0-300 μM; 5-50 hours) does not enhance MTT conversion at 10 μM, while at 100 and 300 μM it produces an inhibitory response, without increasing the LDH signal, i.e., without inducing any detectable degree of cell necrosis. It also produces a decreased oxygen consumption rate (OCR) profiles in CT26 cells^[2].
I3MT-3 (0-300 μM; 48 hours) inhibits CT26 cells proliferate with increasing concentrations of I3MT-3. Confluence of cells treated with HMPSNE is recorded each hour for 48 h by the IncuCyte method^[2].

310.37

Solid

C₁₇H₁₄N₂O₂S

459420-09-8

Room temperature in continental US; may vary elsewhere.

DMSO : 125 mg/mL(402.75 mM;Need ultrasonic)

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

• 1.

  请依序添加每种溶剂： 10% DMSO    90% (20%SBE-β-CDin saline)

  Solubility: 2.08 mg/mL (6.70 mM); Suspended solution; Need ultrasonic

  此方案可获得 2.08 mg/mL (6.70 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

  以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

  将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
• 2.

  请依序添加每种溶剂： 10% DMSO    90%corn oil

  Solubility: ≥ 2.08 mg/mL (6.70 mM); Clear solution

  此方案可获得 ≥ 2.08 mg/mL (6.70 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

  以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。